Retinal Vein Occlusion News and Research

RSS
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.
RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Saving sight of millions by making eye injections safe and comfortable

Saving sight of millions by making eye injections safe and comfortable

FDA approves marketing of AI device to detect diabetic retinopathy

FDA approves marketing of AI device to detect diabetic retinopathy

FDA authorizes marketing of first AI device to detect diabetic retinopathy

FDA authorizes marketing of first AI device to detect diabetic retinopathy

Study suggests potential means of stalling or even reversing diabetes-related blindness

Study suggests potential means of stalling or even reversing diabetes-related blindness

Largest clinical specialty database powers studies that yield key insights

Largest clinical specialty database powers studies that yield key insights

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

VEGF inhibition does not regulate collateral vessels in retinal vein occlusion

VEGF inhibition does not regulate collateral vessels in retinal vein occlusion

Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron announces FDA approval of EYLEA Injection for DME treatment

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema